Bortezomib, Cyclophosphamide, Dexamethasone, and Thalidomide in Treating Patients With Newly Diagnosed, Previously Untreated Multiple Myeloma
Unknown
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cyclophosphamide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Thalidomide may stop the growth of cancer cells by blocking blood flow to the cancer. Giving bortezomib together with cyclophosphamide, dexamethasone, and thalidomide may kill more cancer cell... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2009
Locations: St. Vincent's Comprehensive Cancer Center - Manhattan, New York, New York
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Antenatal Betamethasone Compared to Dexamethasone - "BETACODE TRIAL"
Completed
Antenatal corticosteroids result in substantial decrease in neonatal morbidity and mortality by specifically reducing the risk of respiratory distress syndrome, intraventricular hemorrhage and neonatal death among premature infants. No human randomized study has formally compared betamethasone and dexamethasone, the preferred corticosteroids for antenatal therapy, with regards to their effectiveness in reducing neonatal morbidities and mortality. Our objective was to compare betamethasone with d... Read More
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
01/02/2007
Locations: Stony Brook University Hospital, Stony Brook, New York
Conditions: Respiratory Distress Syndrome, Intraventricular Hemorrhage, Neonatal Mortality